Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Dosing of Natalizumab in MS
NCT03516526Phase 4Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2016
- Primary completion
- Jun 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of natalizumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Amsterdam University Medical Center. Started Nov 2016; status: completed.
02
Drugs
natalizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT03516526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03516526.